Abstract: Humans are sexually dimorphic, with sex being the most persistent difference among humans over the course of our evolutionary history. Beyond the visible sex differences that can be considered true dimorphisms, there are also sex differences at the molecular and cellular scales. The role of these biological sex differences for human health, while being increasingly recognized, have long been underappreciated and underexplored. Frequently, these differences are only recognized in sex-specific diseases, such as genitourinary diseases and cancers. However, given the evidence for sex differences in the most basic aspects of human biology, including metabolism, cellular composition, and immune activity, these differences could have consequences for the etiology and pathophysiology of a majority of diseases. It is thus essential to consider the extent to which these differences may influence the various mechanisms underlying disease processes, response to treatment, and the maintenance of health in order to better improve patient outcomes. Here we review the evidence for a broad array of biological sex differences in humans and discuss how they may relate to observed sex differences in various diseases, with an emphasis on cancer, specifically glioblastoma. We further propose that mathematical approaches can be useful for exploring the extent to which sex differences affect disease outcomes and accounting for those in the development of therapeutic strategies.
INTRODUCTION

1
From a very young age, we are introduced to the dichotomies of sex and gender. Based on external anatomical sexual dimorphism, children are typically assigned a gender at birth and 3 brought up according to distinct gender norms. However, the resulting impacts of this 4 genderedness as a social construct and efforts to avoid gender-based discrimination have at 5 times led to an avoidance of robustly studying and understanding biological sex differences and 6 their role in human medicine. These biological sex differences are related to human sexual increased antibody response. 15 On average, females have higher numbers of CD4+ T-cells than 48 males, as well as a higher ratio of CD4+ to CD8+ cells, and this difference is maintained across 49 all adult ages, even as this ratio increases with age in both males and females. [16] [17] [18] [19] Other studies
50
have found a higher count in total lymphocytes among males, but a higher abundance of granulocytes in blood samples from females. [20] [21] [22] These trends have been observed across 52 different ancestries and various geographic regions, suggesting that these differences are 53 maintained in the presence of various genetic and environmental influences.
55
In addition to differences attributable to genetics, there are also influences due to sex hormones,
56
which are more notable following puberty. Because technology to detect hormones and to
57
produce synthetic hormones has existed much longer than genetic sequencing technology and
58
other sophisticated microbiological approaches, many studies have focused on immune 59 differences attributable to sex steroids. 23 Physiologic levels of estradiol have been shown to be 60 immunostimulatory. 24 One study showed that estradiol may promote the production of 61 corticotropin stimulating hormone by enhancing CRH gene transcription in the hypothalamus,
62
suggesting one mechanism for this effect. 25 Furthermore, hormonal fluctuations during the female 63 menstrual cycle are associated with alterations in T cell numbers. The overall number of 64 regulatory T-cells (Treg) increase during follicular phase and decrease during the luteal phase. 26 Additionally, the relative abundance of type 1 versus type 2 helper T cell (Th1 and Th2,
66
respectively) responses vary with estrogen levels, with Th2 responses being predominant during 67 the follicular phase (when estrogen levels are high) and Th1 responses predominating during the 68 luteal phase. 27, 28 Studies have also shown that estrogens play a dynamic role in wound healing.
69
Estrogens stimulate various growth factor pathways to improve re-innervation and -
70
epithelialization, as well as enhance the formation of granulation tissue. 29 There is an age-related
71
decline in wound healing in healthy females, which is counteracted by hormone replacement
72
therapy with progesterone and either conjugated estrogen or estradiol. 30 
74
Immune 43 Additionally, there has been increased recognition of the role that the well as in hypoglycemia, with females having increased lipolysis relative to males and males having increased carbohydrate oxidation relative to females. 45, 46 There are also differences in protein use and muscle turnover, with slightly less amino acid metabolism in females (particularly reduced leucine oxidation). 46 While these differences are small between young males and 105 females, they may be more pronounced in response to resistance exercise and feeding among older adults. 47, 48 After adjusting for body composition, there does not appear to be a sex difference
107
in overall basal metabolic rate (BMR). 49, 50 However, in one study, the sample size was quite small in order to exclude the effect of circulating sex steroid hormones. 50 Another study noted that
110
females had higher levels of circulating leptin which did not impact residual BMR, although there
111
was an association between residual BMR and the thyroid hormone thyroxine that remained 112 significant for males but not females when the sex cohorts were analyzed separately. 49 
126
in the cingulate region. 54 Still another study found that cerebral glucose metabolism was higher in 127 the orbital frontal region in females than in males, in addition to a global increase, but no difference
128
was found in the left anterolateral prefrontal cortex. 53 The significance of these differences is not
129
well-understood, but they point to potential differences in underlying biology at the cellular level.
131
Some have focused on the role of the menstrual cycle, hypothesizing that metabolic sex 
146
There are also important sex differences in drug metabolism, with some drugs being metabolized 147 slower in females than males and other drugs metabolized faster in females than males. 56 For 148 example, drugs catalyzed by the cytochrome P450 CYP3A have faster rates of clearance in
149
females, who demonstrate twice the level of CYP3A4 expression in their livers. 57 Differences in 150 expression of various cytochrome P450s (CYPs) may be related to their role in steroid hormone synthesis and metabolism. 58 Other drugs have slower clearance in females than males, and may
152
thus have higher toxicity. 56 This difference has also been observed among children treated with 6-mercaptopurine for leukemia, with males requiring higher levels of the drug to attain similar 154 efficacy. 59, 60 Sex differences in growth hormone secretion patterns may be just one factor contributing to observed sex differences in CYP expression, through effects on expression of STAT5b, which has regulatory effects on a number of CYP genes. 61, 62 or existence of gonadal hormones, and are linked to developmental differences between the fetal losses than female, 63 
297
Additionally, glycolytic metabolite levels (pyruvate and the lactate/pyruvate ratio) stratified male survival, and not female, among grade II glioma patients. 119 A different study used advanced 299 imaging and found differences in magnetic resonance imaging (MRI) metrics and relative 300 metabolite levels between male and female high-grade glioma rat models. They concluded that 301 the male tumors were more aggressive than female tumors, warranting further investigation in 302 human subjects. 122 With the increased utilization of FDG-PET and other advanced imaging on 303 brain tumor patients and the potential for this information to be used to predict tumor grade and patient prognosis, 123 it will be increasingly important that we understand how sex impacts tumor 305 metabolism and patient outcomes.
system in the CNS is now known to have both adaptive and innate components, with antigens triggering both T cell and macrophage responses. Ideally, the immune system combats cancerous secrete immunosuppressive cytokines and manipulate immune activity. 124, 125 There is very little 314 information on sex differences in the neuroimmune system based on the analysis of human 315 subjects, but microglia are known to play an important role in human brain development, and rat 316 models have shown sex differences in the abundance of microglia and effect of T-cells on the 317 development of rat brains. 38 Considering the previously described role of X inactivation in immune 318 activity and the observed immune sex differences in the rest of the body, one would hypothesize 319 that the interactions between GBM cells and the immune system might also be impacted by sex.
320
Two studies using case-control methods found an inverse relationship between pre-diagnostic
321
IgE levels and risk for high-grade glioma among females only. 126, 127 Contrarily, another study 322 found an inverse relationship between pre-diagnostic IgE levels and glioma risk among all patients
323
and did not find that this relationship was more significant among females. 128 At baseline, males
324
were found to have higher levels of total IgE compared to females among both glioma cases
325
(tested after diagnosis) and healthy controls. 124 Considering the vast potential impact of sex 326 differences on immune-glioma interactions and the necessity of understanding sex's role in these
327
interactions when deploying immune-dependent treatments (e.g., chimeric antigen receptor
328
(CAR) T cell therapy), there is a startling shortage of research on this subject.
330
Sex differences in glioma related to hormones
331
The sex differences in glioblastoma incidence have been observed across age groups, 133 There is minimal research on the impact of sex hormones on glioma growth or 350 treatment response and the role of sex hormones in the observed sex differences in prognosis
351
and outcome has yet to be elucidated.
353
Other observed sex differences in glioma
354
Genetic differences, either in coding or expression, are thought to play a role in the sex differences 355 observed in GBM. A comprehensive study of both the mutation and expression profiles of multiple indicating that there were less sex-biased patterns in gene coding and expression in glioma compared to cancers like bladder urothelial carcinoma and thyroid carcinoma. 134 Despite being a sex differences in GBM. By applying a framework for assessing mutational clonality to the genetic 361 coding data of glioma patients, one study found that females had higher overall and subclonal 362 mutation burden than males among both LGG and GBM groups. While the X chromosome 363 contributed to the higher overall mutation burden in females, other chromosomes were implicated 364 in this finding as well. 135 Their results suggest that sex-biased mutagenesis may play a role in 365 glioma development and that sex chromosomes may play an important role in cancer evolution.
366
Focusing on genetic expression, a recent study on GBM patients used a joint and individual these volumes have a sex-specific impact on overall survival. 139 Taken together, these studies
383
emphasize the need to consider sex differences in studies of glioma genetics and neuroimaging,
384
particularly in the growing field of radiomics.
386
COMPLEX ADAPTIVE SYSTEMS AND MODELING
387
During a meeting on sex differences in the brain and brain tumors sponsored by the James S.
388
McDonnell Foundation in March 2018, we concluded that understanding the contributions of sex 389 to health and disease is imperative for advancing precision medicine. The myriad differences 390 between the sexes and their impact on normal biology and pathology are highly interconnected 391 and complex, necessitating mathematical and computational approaches for investigation.
392
Mechanistic mathematical models, including differential equation models, can allow us to bridge 393 spatiotemporal scales in testing hypotheses about the impacts of biological sex differences on 394 health and disease outcomes. Agent-based models, in particular, can be useful for discovering 395 emergent phenomena in complex adaptive systems, integrating various processes that have been
396
well-described in isolation to better understand their interacting effects. Computational machine 397 learning models can be useful for identifying patterns in data that provide further understanding
398
of the extent to which various biological sex differences affect health outcomes. Machine learning 399 models can also be combined with mechanistic models wherein we constrain algorithms with well-400 understood phenomena in order to better elucidate that which is less well understood. In order to 401 fully make use of these quantitative methods, it is vital to collect data related to sex as part of 402 clinical studies. In particular, clinical trial coordinators should pre-consider which data might be 403 needed to examine sex differences prior to initiating a clinical study (for example, data on subjects' 404 menstrual status and noting any type of hormone therapy a subject is taking, or explicitly 405 measuring subjects' hormone levels, including sex steroids other than estrogen/testosterone).
concerns to improve data collection. 135 To reduce the impact of gendered social norms for self- 
